AU776652B2 - Method of inhibiting a chaperone protein - Google Patents

Method of inhibiting a chaperone protein Download PDF

Info

Publication number
AU776652B2
AU776652B2 AU37406/00A AU3740600A AU776652B2 AU 776652 B2 AU776652 B2 AU 776652B2 AU 37406/00 A AU37406/00 A AU 37406/00A AU 3740600 A AU3740600 A AU 3740600A AU 776652 B2 AU776652 B2 AU 776652B2
Authority
AU
Australia
Prior art keywords
protein
client
coumarin
polypeptide
chaperone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU37406/00A
Other languages
English (en)
Other versions
AU3740600A (en
Inventor
Monica G. Marcu
Leonard M. Neckers
Theodor W. Schulte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU3740600A publication Critical patent/AU3740600A/en
Application granted granted Critical
Publication of AU776652B2 publication Critical patent/AU776652B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
AU37406/00A 1999-03-12 2000-03-10 Method of inhibiting a chaperone protein Ceased AU776652B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12413599P 1999-03-12 1999-03-12
US60124135 1999-03-12
PCT/US2000/006482 WO2000053169A2 (fr) 1999-03-12 2000-03-10 Methode utilisee pour inhiber une proteine chaperonne

Publications (2)

Publication Number Publication Date
AU3740600A AU3740600A (en) 2000-09-28
AU776652B2 true AU776652B2 (en) 2004-09-16

Family

ID=22412989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37406/00A Ceased AU776652B2 (en) 1999-03-12 2000-03-10 Method of inhibiting a chaperone protein

Country Status (5)

Country Link
EP (1) EP1161231A2 (fr)
JP (1) JP2003523313A (fr)
AU (1) AU776652B2 (fr)
CA (1) CA2367108A1 (fr)
WO (1) WO2000053169A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858331B2 (en) 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
WO2002094259A1 (fr) * 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composes inhibant hsp90 et stimulant hsp70 et hsp40, utiles pour prevenir ou traiter des maladies associees a l'agregation de proteines et a la formation d'amyloides
EP1457499A1 (fr) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibiteurs de protéine de choc thermique (HSP90) extracellulaire
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
WO2005000778A1 (fr) * 2003-06-27 2005-01-06 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de proteines de la famille hsp90
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
WO2006050501A2 (fr) * 2004-11-03 2006-05-11 University Of Kansas Analogues de novobiocine en tant qu'agents anticancereux
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
JP5700409B2 (ja) 2008-11-14 2015-04-15 国立大学法人京都大学 Ｈｓｐ９０を標的にした新規抗がんキメラペプチド
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
CN101942017B (zh) 2009-07-07 2013-08-14 清华大学 一种新的肿瘤标志物
DE102009054302A1 (de) 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
DE102010046837A1 (de) 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
WO2012162054A1 (fr) * 2011-05-20 2012-11-29 The University Of Kansas Inhibiteurs dynamiques de la protéine de choc thermique 90

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216014A (en) * 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216014A (en) * 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORER V ET AL CANCER RESEARCH, JUNE 1986,46(6),PGS 2929-2935 *
WANG B H ET AL PHYTOCHEMISTRY,MARCH 1997,44(5),PGS 787-796 *

Also Published As

Publication number Publication date
WO2000053169A2 (fr) 2000-09-14
JP2003523313A (ja) 2003-08-05
EP1161231A2 (fr) 2001-12-12
AU3740600A (en) 2000-09-28
WO2000053169A8 (fr) 2001-01-11
CA2367108A1 (fr) 2000-09-14

Similar Documents

Publication Publication Date Title
AU776652B2 (en) Method of inhibiting a chaperone protein
Gupta et al. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer
Henry et al. Flavone antagonists bind competitively with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) to the aryl hydrocarbon receptor but inhibit nuclear uptake and transformation
Ihle et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling
Zhang et al. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase
EP2477494B1 (fr) Ligands de na/k-atpase, antagonistes ouabaïnes, leurs essais et leurs utilisations
Zhang et al. Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner
WO2007067752A2 (fr) Compositions et procedes de traitement
Li et al. Simultaneous LC-MS/MS bioanalysis of alkaloids, terpenoids, and flavonoids in rat plasma through salting-out-assisted liquid-liquid extraction after oral administration of extract from Tetradium ruticarpum and Glycyrrhiza uralensis: A sample preparation strategy to broaden analyte coverage of herbal medicines
CA2720396A1 (fr) Composition pharmaceutique
WO2023023376A2 (fr) Sulfonyl-triazoles utiles en tant que ligands de kinases covalents
Hamdan et al. Inhibition of mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine derivative, S-15176
Liu et al. Phillygenin attenuates inflammatory responses and influences glucose metabolic parameters by inhibiting Akt activity
Cleary et al. Effects of amphotericin B and caspofungin on histamine expression
CN104211747B (zh) 5’-磷酸-n6-（3-羟基苯基）腺苷的制备及医药用途
Lei et al. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments
US8586626B2 (en) Metabolites of wortmannin analogs and methods of using the same
Ye et al. Total glucosides of paeony alleviates cGAS-STING-mediated diseases by blocking the STING-IRF3 interaction
Abel et al. Interaction of A3 adenosine receptor ligands with the human multidrug transporter ABCG2
Gowans et al. Ophiobolin A covalently targets complex IV leading to mitochondrial metabolic collapse in cancer cells
Chimirri et al. Synthesis, biological activity, pharmacokinetic properties and molecular modelling studies of novel 1H, 3H-oxazolo [3, 4-a] benzimidazoles: non-nucleoside HIV-1 reverse transcriptase inhibitors
Phizackerley et al. Mechanism of degradation of an α-Keto-epoxide, a model for the warhead for various proteasome inhibitor anticancer agents
Hirasawa et al. Pharmacological analysis of the inflammatory exudate-induced histamine production in bone marrow cells
KR20090053504A (ko) 피리미딘-2,4,6-트라이온 유도체를 함유하는 Ｈｓｐ９０억제제 및 이를 이용한 항암제
Anand et al. Prediction of novel drug targets in Ergosterol biosynthesis pathway: a proposed mechanism of anticandidal activity of green tea phytocompounds